Gearing up for a phase III trial with its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy next year, Kite Pharma Inc. upsized its follow-on public offering by 485,000 shares, pricing about 3.4 million shares at $54 each for gross proceeds of about $188.1 million.
The Santa Monica, Calif.-based company's financing comes as would-be CAR T-cell player Juno Therapeutics Inc., of Seattle, revs for a whopper initial public offering (IPO) that could raise $191 million. A spokesperson for the company said Kite could not comment because of SEC quiet period rules.
Heartening investors by way of phase I/IIa data over the summer with KTE-C19, its anti-CD19 CAR T-cell therapy for aggressive non-Hodgkin's lymphoma, Kite said at the time that it plans a pivotal study early in 2015 in diffuse large B-cell lymphoma. The